---

Query Drug：Belzutifan

Query Time：2024-04-11 13:18:28

*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice.

---

About the Drug

Belzutifan is used in people with von Hippel-Lindau disease (VHL), a rare genetic condition that can cause tumors to develop in certain organs of the body.

Belzutifan is for use in adults with VHL who need treatment for certain tumors of the kidneys, pancreas, or brain and spinal cord. Belzutifan is used when these tumors do not require surgery right away.

Related Diseases

Drug belzutifan

RXCUI: 2567226

May Treat

• von Hippel-Lindau Disease

Similar Drugs

[may_treat] von Hippel-Lindau Disease

Source MEDRT

• belzutifan

[Mechanism of Action] Cytochrome P450 3A4 Inducers

Source FDASPL

• enzalutamide

• dabrafenib

• eslicarbazepine

• oritavancin

• osimertinib

• carbamazepine

• ivosidenib

• erdafitinib

• clobazam

• pitolisant

• cenobamate

• amprenavir

• belzutifan

• omaveloxolone

• aprepitant

• topiramate

• deferasirox

• mitotane

[Mechanism of Action] Cytochrome P450 3A4 Inducers

Source DAILYMED

• enzalutamide

• dabrafenib

• eslicarbazepine

• oritavancin

• osimertinib

• carbamazepine

• ivosidenib

• erdafitinib

• clobazam

• cenobamate

• amprenavir

• belzutifan

• omaveloxolone

• aprepitant

• topiramate

• deferasirox

• mitotane

[Mechanism of Action] Gene Transcription Modulation

Source MEDRT

• viltolarsen

• belzutifan

• nadofaragene firadenovec

[Mechanism of Action] Hypoxia-inducible Factor 2 alpha Inhibitors

Source FDASPL

• belzutifan

[Mechanism of Action] Hypoxia-inducible Factor 2 alpha Inhibitors

Source DAILYMED

• belzutifan

[Phamacological Category] Hypoxia-inducible Factor Inhibitor

Source FDASPL

• belzutifan

[Phamacological Category] Hypoxia-inducible Factor Inhibitor

Source DAILYMED

• belzutifan

Orange Book

[Last update] 2024-03-08

Labelers

Belzutifan's Innovator is MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Drug Products

The unique dosage forms from the innovator include：1. TABLET;ORAL.

Index	Route	Brand Name	Labeler	Approval Date	Dosage
1	TABLET;ORAL	WELIREG	MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC	Aug 13, 2021	40MG

Drug Patents

This drug still has 2 effective patents.

Patent Number	Submission Date	Expiration Date	Drug Substance Patent?	Drug Product Patent?
9908845	Sep 9, 2021	Sep 5, 2034	Y	Y
9969689	Sep 9, 2021	Sep 5, 2034	Y	Y

Related Company's Product Pipelines

The innovator MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC's portolio contains products with the following 6 API(s)： DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE，APREPITANT，BELZUTIFAN，DORAVIRINE，POSACONAZOLE，CILASTATIN SODIUM; IMIPENEM; RELEBACTAM